DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

908 Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on
metabolism of statins in human hepatocytes. Drug Metab
Disp, 2002b, 30:1280–1287.
Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on
metabolic interactions between gemfibrozil and statins. J
Pharmacol Exp Ther, 2002c, 301:1042–1051.
Radhakrishnan A, Goldstein JL, McDonald JG, Brown MS.
Switch-like control of SREBP-2 transport triggered by small
changes in ER cholesterol: A delicate balance. Cell Metab,
2008, 8:512–521.
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to
prevent vascular events in men and women with elevated C-
reactive protein. N Engl J Med, 2008, 359:2195–2207.
Robins SJ. Targeting low high-density lipoprotein cholesterol for
therapy: Lessons from the Veterans Affairs High-Density
Lipoprotein Intervention Trial. Am J Cardiol, 2001, 88(suppl):
19N–23N.
Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the
key effector of reverse cholesterol transport ATP-binding cassette
A1 in monocytoid cells by niacin. Biochem Pharmacol,
2004, 67:411–419.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary
prevention of coronary heart disease in men with low
levels of high-density lipoprotein cholesterol. N Engl J Med,
1999, 341:410–418.
Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in
patients hospitalized with coronary artery disease: An analysis
of 136,905 hospitalizations in Get With The Guidelines.
Am Heart J, 2009, 157:111–117.
Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the
risk of coronary heart disease: 10 158 incident cases among
262 525 participants in 29 Western prospective studies.
Circulation, 2007, 115:450–458.
Schachter M. Chemical, pharmacokinetic and pharmacodynamic
properties of statins: An update. Fundam Clin Pharmacol,
2005, 19:117–125.
Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect
of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin
Pharmacol Ther, 2004, 75:455–463.
Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic
alterations of 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitors: Drug–drug interactions and
interindividual differences in transporter and metabolic
enzyme functions. Pharmacol Ther, 2006, 112:71–105.
Shlipak MG, Simon JA, Vittinghoff E, et al. Estrogen and progestin,
lipoprotein(a), and the risk of recurrent coronary heart
disease events after menopause. JAMA, 2000, 283:1845–1852.
Sniderman A. Targets for LDL-lowering therapy. Curr Opin
Lipidol, 2009, 20:282–287.
Sniderman AD, Marcovina SM. Apolipoprotein A1 and B. Clin
Lab Med, 2006, 26:733–750.
Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal
rhabdomyolysis. N Engl J Med, 2002, 346:539–540.
Steinberg D, Witztum JL. Is the oxidative modification hypothesis
relevant to human atherosclerosis? Do the antioxidant trials
conducted to date refute the hypothesis? Circulation, 2002,
105:2107–2111.
Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal
cholesterol absorption by ezetimibe in humans. Circulation,
2002, 106:1943–1948.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Tall AR. CETP inhibitors to increase HDL cholesterd levels.
Engl J Med, 2007, 356:1364–1366.
Tall AR, Yvan-Charvet L, Terasaka N, et al. HDL, ABC transporters,
and cholesterol efflux: Implications for the treatment
of atherosclerosis. Cell Metabol, 2008, 7:365–375.
Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis
improves endothelium-dependent vasodilatation in hypercholesterolemic
humans. Circulation, 1997, 95:76–82.
The Expert Panel. Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). Final report. Circulation,
2002, 106:3143–3421.
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy.
JAMA, 2003, 289:1681–1690.
Thompson PD, Clarkson PM, Rosenson RS. An assessment of
statin safety by muscle experts. Am J Cardiol, 2006, 97(suppl):
69C–76C.
Vakkilainen J, Steiner G, Ansquer J-C, et al. Relationships
between low-density lipoprotein particle size, plasma lipoproteins,
and progression of coronary artery disease. The Diabetes
Atherosclerosis Intervention Study (DAIS). Circulation, 2003,
107:1733–1737.
Van Eck M, Singaraja RR, Ye D, et al. Macrophage ATP-binding
cassette transporter A1 overexpression inhibits atherosclerotic
lesion progression in low-density lipoprotein receptor knockout
mice. Arterioscler Thromb Vasc Biol, 2006, 26:929–934.
Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1
and ABCG1, but not SR-BI, promote macrophage reverse cholesterol
transport in vivo. J Clin Invest, 2007, 117: 2216–2224.
Wickramasinghe SR, DeFilippis AP, Lloyd-Jones DM,
Blumenthal RS. A convenient tool to profile patients for
generalized cardiovascular disease risk in primary care. Am J
Cardiol, 2009, 103:1174–1177.
Wilke RA, Lin D, Roden D, et al. Identifying genetic risk factors
for serious adverse drug reactions. Nat Rev Drug Discov, 2007,
6:904–916.
Williams JK, Sukhova GK, Herrington DM, Libby P. Pravastatin
has cholesterol-lowering independent effects on the artery wall
of atherosclerotic monkeys. J Am Coll Cardiol, 1998,
31:684–691.
Wise A, Foord SM, Fraser NJ, et al. Molecular identification of
high and low affinity receptors for nicotinic acid. J Biol Chem,
2003, 278:9869–9874.
Witztum JL, Steinberg D. The oxidative modification hypothesis
of atherosclerosis: Does it hold for humans? Trends
Cardiovasc Med, 2001, 11:93–102.
Wong K, Ryan RO. Characterization of apolipoprotein A-V
structure and mode of plasma triacylglycerol regulation. Curr
Opin Lipidol, 2007, 18:319–324.
Wong WW-L, Dimitroulakos J, Minden MD, Penn LZ. HMG-
CoA reductase inhibitors and the malignant cell: The statin
family of drugs as triggers of tumor-specific apoptosis.
Leukemia, 2002, 16:508–519.
Yusuf S. Two decades of progress in preventing vascular disease.
Lancet, 2002, 360:2–3.
Zhang Z-J, Cheng Q, Jiang G-X, Marroquin OC. Statins in prevention
of repeat revascularization after percutaneous coronary
intervention—A meta-analysis of randomized clinical
trials. Pharmacol Res, 2010, 61:316–320.